Design Therapeutics Reports $20.3 Million Third-Quarter 2026 Net Loss

The Tip Desk · November 11, 2026 · 3 min read

Third-quarter 2026 research and development expenses were $16.9 million. Cash, cash equivalents and investment securities were $208.6 million as of September 30, 2026, down $14.2 million from $222.8 million at March 31, 2026.

Design Therapeutics, Inc. (DSGN), a clinical-stage biotechnology company developing GeneTAC® therapies for serious degenerative genetic diseases, reported a net loss of $20.3 million for the quarter ended September 30, 2026, as research and development spending held near the prior quarter’s level.

Research and development expenses were $16.9 million for the three months ended September 30, 2026, up from $16.4 million in the second quarter. General and administrative expenses were $5.3 million. Total operating expenses were $22.2 million. Other income, net, was $1.9 million. Net loss per share, basic and diluted, was $0.32. Weighted-average shares outstanding were 63.0 million.

Cash, cash equivalents and investment securities were $208.6 million as of September 30, 2026. The company said that balance provides a strong financial runway. Stockholders’ equity was $202.2 million. Total assets were $216.8 million.

The Friedreich ataxia program remained the near-term clinical focus. The Phase 1/2 multiple ascending dose RESTORE-FA trial of DT-216P2 is ongoing. Design expects to provide an update on its registrational plans in the fourth quarter of 2026, with data following 12 weeks of treatment expected in the first quarter of 2027. Those milestones were already outlined after second-quarter trial modifications that kept 1 mpk as the planned go-forward dose, intended to enroll 10 patients in the 12-week cohort, specified endogenous blood FXN protein percent change from baseline as the primary efficacy endpoint, and explored a dose level above 1 mpk.

Chairperson and chief executive officer Pratik Shah said the company remains focused on evaluating DT-216P2 over longer treatment durations and preparing for the next stage of clinical development in Friedreich ataxia. Clinical readouts expected in 2027, he said, will help guide the programs as the company pursues its GeneTAC® platform.

In myotonic dystrophy type 1, the Phase 1 multiple-ascending dose trial of DT-818 is ongoing. Dosing in DM1 patients had been initiated in the second quarter, after the company had said in the first quarter that it expected to begin dosing in the first half of 2026. Design anticipates reporting data from that trial in 2027. Shah said the Phase 1 trial is evaluating an approach designed to selectively reduce transcription of the mutant DMPK allele, targeting the source of toxic RNA.

A Phase 2 biomarker trial of DT-168 in Fuchs endothelial corneal dystrophy is ongoing to evaluate safety, tolerability and corneal endothelium biomarkers in patients scheduled for corneal transplant surgery, with data expected in 2027. That timing slipped from data anticipated in the second half of 2026 in the first-quarter release, which the company attributed to a delay in the anticipated supply of DT-168 blow-fill-seal eye droppers. Design continues to advance preclinical characterization of several candidate molecules for its Huntington’s disease program.

For the nine months ended September 30, 2026, research and development expenses were $47.7 million, general and administrative expenses were $16.4 million, and net loss was $58.1 million, or $0.93 a share.

The company said it remains focused on evaluating DT-216P2 over longer treatment durations and preparing for the next stage of clinical development in Friedreich ataxia, with a registrational-plans update expected in the fourth quarter of 2026 and 12-week RESTORE-FA data expected in the first quarter of 2027.